Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
From worst-case to reality - Case studies illustrating tiered refinement of consumer exposure to cosmetic ingredients.
Tozer S, Alexander-White C, Amin R, Audebert F, Barratt C, O'Brien J, Burke T, Bury D, Nguea HD, Dimopoulou M, Farahmand S, Fritz S, Gerber E, Giusti A, Goodwin W, Kirsch T, Oreffo V, McNamara C. Tozer S, et al. Among authors: audebert f. Regul Toxicol Pharmacol. 2023 Sep;143:105436. doi: 10.1016/j.yrtph.2023.105436. Epub 2023 Jul 8. Regul Toxicol Pharmacol. 2023. PMID: 37429522 Free article.
Assessment of undesirable events in cosmetic market surveillance: background, description and use of a causality assessment method in cosmetovigilance.
Bons B, Audebert F, Bitaudeau C, Cachin N, Colson L, Farr C, Fix LA, Gilmour N, Gorni R, Griffiths M, Harris B, Holle V, Kirk S, Meredith E, Pari C, Poinsot P, Renner G; Members of the Colipa Cosmetovigilance Task Force. Bons B, et al. Among authors: audebert f. Regul Toxicol Pharmacol. 2010 Dec;58(3):349-53. doi: 10.1016/j.yrtph.2010.06.015. Epub 2010 Jul 7. Regul Toxicol Pharmacol. 2010. PMID: 20619309 No abstract available.
AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.
Pantke A, Kollan C, Gunsenheimer-Bartmeyer B, Jensen BO, Stephan C, Degen O, Schürmann D, Kurth T, Bremer V, Koppe U; HIV-1 Seroconverter Cohort and the ClinSurv HIV Cohort. Pantke A, et al. Infection. 2024 Apr;52(2):637-648. doi: 10.1007/s15010-024-02188-y. Epub 2024 Feb 21. Infection. 2024. PMID: 38381307 Free PMC article.
Efficacy of a Mouthwash Containing CHX and CPC in SARS-CoV-2-Positive Patients: A Randomized Controlled Clinical Trial.
Bonn EL, Rohrhofer A, Audebert FX, Lang H, Auer DL, Scholz KJ, Schuster P, Wenzel JJ, Hiller KA, Buchalla W, Gottsauner JM, Vielsmeier V, Schmidt B, Cieplik F. Bonn EL, et al. Among authors: audebert fx. J Dent Res. 2023 Jun;102(6):608-615. doi: 10.1177/00220345231156415. Epub 2023 Mar 21. J Dent Res. 2023. PMID: 36942423 Free PMC article. Clinical Trial.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Correction to: Contribution of High Viral Loads, Detection of Viral Antigen and Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity.
Buder F, Bauswein M, Magnus CL, Audebert F, Lang H, Kundel C, Distler K, Reuschel E, Lubnow M, Müller T, Lunz D, Graf B, Schmid S, Müller M, Poeck H, Hanses F, Salzberger B, Peterhoff D, Wenzel JJ, Schmidt B, Lampl BMJ. Buder F, et al. Among authors: audebert f. J Infect Dis. 2023 Feb 14;227(4):605. doi: 10.1093/infdis/jiac123. J Infect Dis. 2023. PMID: 35869700 Free PMC article. No abstract available.
Mouthrinses against SARS-CoV-2 - High antiviral effectivity by membrane disruption in vitro translates to mild effects in a randomized placebo-controlled clinical trial.
Meister TL, Gottsauner JM, Schmidt B, Heinen N, Todt D, Audebert F, Buder F, Lang H, Gessner A, Steinmann E, Vielsmeier V, Pfaender S, Cieplik F. Meister TL, et al. Among authors: audebert f. Virus Res. 2022 Jul 15;316:198791. doi: 10.1016/j.virusres.2022.198791. Epub 2022 May 2. Virus Res. 2022. PMID: 35504446 Free PMC article. Clinical Trial.
55 results